Rituximab

unknown (auto-discovered: peptides-regenerative)

Also known as: Rituximab combined with cyclosporine

Not graded

Classification

Biologic

Regulatory Status

investigational; registered trials: NCT07884708, NCT07861204 (PHASE2/PHASE2/PHASE3)

Unofficial source

Sources

Review

pending review

Overview

Unknown — Rituximab was found by open discovery on 2026-10-26 and has not been researched yet.

Known

n/a

Unknown

Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.

Study details: trial conditions, not guidance

These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.

Doses as found in each source, with its grade. What was found, not a direction.

Studies, trials and professional sources

n/a

Reddit, Facebook, Instagram, forums and blogs

n/a

Not gradedRituximab is being studied in a registered trial: Chidamide, Lenalidomide, and Rituximab in Newly Diagnosed Elderly/unFit DE-DLBCL (NCT07884708; PHASE2; RECRUITING; sponsor The First Affiliated Hospital with Nanjing Medical University; intervention "Chidamide in combination with Lenalidomide and Rituximab (CR2)" (DRUG)).
Not gradedRituximab is being studied in a registered trial: Combination of Rituximab and Cyclosporine in the Treatment of Primary Membranous Nephropathy (NCT07861204; PHASE2/PHASE3; RECRUITING; sponsor Peking University First Hospital; intervention "Rituximab combined with cyclosporine" (DRUG)).

Educational reference only — not medical advice.

What people report (anecdote)

Adverse events:

None recorded in our sources.

Effects measured:

Human trials: none found.

ANECDOTE

Loading…